Key Stats for Moderna Stock
- Price change for Moderna stock in last 1 month: -25%
- $MRNA Stock Price as of Jul. 31: $55
- 52-Week High: $86
- $MRNA Stock Price Target: $49
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Moderna (MRNA) stock dropped about 5% even though the biotech actually beat Wall Street’s expectations across the board.
The company reported a loss of $1.97 per share, smaller than the $2.06 loss analysts had projected. Revenue came in at $145 million, well above the $103 million estimate.
Even full-year revenue guidance came in ahead of what the Street was expecting.
So why did Moderna stock fall on a quarter that beat estimates? The answer seems to come down to the pipeline, not the numbers.
Moderna announced that its norovirus vaccine candidate, mRNA-1403, failed to meet the statistical bar for early success at its Phase 3 interim analysis. The company is now preparing to enroll an additional patient cohort to strengthen the data, which pushes out the timeline for this program.
Investors often weigh pipeline setbacks like this heavily, even when quarterly financials look strong, since future drug approvals are a huge part of how biotech stocks get valued.
There were plenty of positives elsewhere in the report. Moderna reiterated its plan for up to 10% revenue growth in 2026.
The company also improved its full-year operating expense outlook by about $0.2 billion and now expects to end the year with $4.7 billion to $5.2 billion in cash and investments, an improvement from prior guidance.
Net loss for the quarter improved 5% year over year to $782 million, helped by lower research and development costs and continued spending discipline.
On the pipeline side, Moderna is preparing for a potential approval of its seasonal flu vaccine, mFLUSIVA, which received a unanimous recommendation from the FDA’s vaccine advisory committee ahead of an August 5 decision date.
If approved, it would become the company’s fifth approved product. The company also highlighted strong five-year data for its cancer therapy Intismeran, developed with Merck, which showed a 49% reduction in risk of recurrence or death when combined with Keytruda in adjuvant melanoma patients.
A Phase 3 readout for that same melanoma program is still expected potentially later in 2026, alongside data from Moderna’s propionic acidemia rare disease program.
See analysts’ growth forecasts and price targets for Moderna stock (It’s free) >>>
What the Market Is Telling Us About Moderna Stock
A stock falling despite a clear earnings and revenue beat tells you the market is looking past this quarter’s numbers and focusing on what comes next.
The norovirus trial miss is a reminder that Moderna’s story right now is less about current commercial revenue, which remains small, and more about whether its broader pipeline in oncology, rare disease, and new vaccines can deliver.
With multiple pivotal readouts still ahead this year, including the melanoma Phase 3 data and the PA rare disease results, Moderna stock is likely to keep trading on pipeline headlines more than quarterly financial performance.
Investors will be watching closely to see whether the upcoming flu vaccine decision and other trial results can help shift sentiment back in the company’s favor.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Moderna Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
